Rhiannon J. Wood

This study shows that infusing the TrkB agonist 7,8-dihydroxyflavone into the cerebrospinal fluid does not promote myelin repair in cuprizone or EAE models of multiple sclerosis.

This study shows that acute treatment with TrkB agonist LM22A-4 after pediatric TBI reduces tissue damage and preserves myelin integrity, with some behavioral improvements.

This study shows environmental enrichment stimulates structural remodeling of pre-existing myelinated axons and oligodendrocytes in young adult mice, increasing axon diameter and myelin thickness without enhancing new myelin production.

The paper compares oligodendrocyte generation dynamics in mice and humans, finding that mouse precursors do not vary division times and that murine oligodendrogenesis resembles human patterns.

This study compares two TrkB agonists, TDP6 and LM22A-4, in a mouse model of demyelination, finding that LM22A-4 promotes remyelination via indirect Trk receptor transactivation.

This study shows that a BDNF mimetic targeting TrkB promotes myelin repair in a mouse model of demyelination by enhancing oligodendrocyte differentiation and remyelination.